{"id":73983,"date":"2026-04-20T13:04:04","date_gmt":"2026-04-20T07:34:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=73983"},"modified":"2026-04-20T13:04:06","modified_gmt":"2026-04-20T07:34:06","slug":"piramal-pharma-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/","title":{"rendered":"Piramal Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"},"content":{"rendered":"<p>Piramal Pharma (NSE: PPLPHARMA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Piramal Pharma trading at Rs 182 \u2014 against a 52-week high of Rs 268 and a 1-year return of -20% \u2014 the Q4 FY26 results will be a pivotal event for investors tracking the Pharma\/CDMO sector.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 2,400\u20132,600 Cr, with PAT expectations of Rs 28\u201355 Cr and margin projections of EBITDA 16\u201319%. This article covers the Piramal Pharma Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings, and answers to the most commonly searched investor questions.<\/p><p>Get free investment predictions on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Piramal_Pharma_Q4_Results_2026_Date\" title=\"Piramal Pharma Q4 Results 2026 Date\">Piramal Pharma Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Piramal_Pharma_Q4_FY26_Earnings_Estimates\" title=\"Piramal Pharma Q4 FY26 Earnings Estimates\">Piramal Pharma Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#5_Key_Factors_That_Will_Drive_Piramal_Pharma_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Piramal Pharma Q4 FY26 Performance\">5 Key Factors That Will Drive Piramal Pharma Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#CDMO_Revenue_Acceleration\" title=\"CDMO Revenue Acceleration\">CDMO Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Complex_Hospital_Generics_CHG_Improvement\" title=\"Complex Hospital Generics (CHG) Improvement\">Complex Hospital Generics (CHG) Improvement<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#India_Consumer_Healthcare_Revenue\" title=\"India Consumer Healthcare Revenue\">India Consumer Healthcare Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#PAT_Recovery_to_Positive\" title=\"PAT Recovery to Positive\">PAT Recovery to Positive<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Debt_Reduction_and_Financial_Health\" title=\"Debt Reduction and Financial Health\">Debt Reduction and Financial Health<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#5_Risks_to_Watch_in_Piramal_Pharma_Q4_FY26\" title=\"5 Risks to Watch in Piramal Pharma Q4 FY26\">5 Risks to Watch in Piramal Pharma Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#CDMO_Execution_and_Capacity_Utilisation\" title=\"CDMO Execution and Capacity Utilisation\">CDMO Execution and Capacity Utilisation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#CHG_Price_Pressure_in_Sterile_Injectables\" title=\"CHG Price Pressure in Sterile Injectables\">CHG Price Pressure in Sterile Injectables<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Regulatory_Risk_%E2%80%94_US_FDA\" title=\"Regulatory Risk \u2014 US FDA\">Regulatory Risk \u2014 US FDA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#High_Debt_Levels\" title=\"High Debt Levels\">High Debt Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#India_Consumer_Healthcare_Competition\" title=\"India Consumer Healthcare Competition\">India Consumer Healthcare Competition<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Piramal_Pharma_Share_Price_and_Analyst_Ratings\" title=\"Piramal Pharma Share Price and Analyst Ratings\">Piramal Pharma Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#What_is_the_Piramal_Pharma_Q4_results_2026_date\" title=\"What is the Piramal Pharma Q4 results 2026 date?\">What is the Piramal Pharma Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#What_is_the_Piramal_Pharma_Q4_FY26_PAT_estimate\" title=\"What is the Piramal Pharma Q4 FY26 PAT estimate?\">What is the Piramal Pharma Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#What_is_Piramal_Pharmas_share_price_ahead_of_Q4_results\" title=\"What is Piramal Pharma&#8217;s share price ahead of Q4 results?\">What is Piramal Pharma&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Will_Piramal_Pharma_declare_a_dividend_in_Q4_2026\" title=\"Will Piramal Pharma declare a dividend in Q4 2026?\">Will Piramal Pharma declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Which_analysts_have_a_Buy_rating_on_Piramal_Pharma\" title=\"Which analysts have a Buy rating on Piramal Pharma?\">Which analysts have a Buy rating on Piramal Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#What_were_Piramal_Pharma_Q3_FY26_results\" title=\"What were Piramal Pharma Q3 FY26 results?\">What were Piramal Pharma Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Is_Piramal_Pharma_a_good_investment_ahead_of_Q4_results\" title=\"Is Piramal Pharma a good investment ahead of Q4 results?\">Is Piramal Pharma a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Q4_Results_2026_Date\"><\/span><strong>Piramal Pharma Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 FY26 Results Date<\/strong><\/td><td><strong>Sector<\/strong><\/td><\/tr><tr><td><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS<\/a><\/td><td>April 9, 2026<\/td><td>IT Services<\/td><\/tr><tr><td><a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a><\/td><td>April 23, 2026<\/td><td>IT Services<\/td><\/tr><tr><td>Piramal Pharma<\/td><td>May 2026 (Expected)<\/td><td>See article<\/td><\/tr><\/tbody><\/table><\/figure><p>Piramal Pharma has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet to approve audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a CMP of Rs 182, investors will closely watch this announcement for revenue growth confirmation and FY27 guidance.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Piramal Pharma, operating in the Pharma\/CDMO sector, Q4 will reveal whether earlier-quarter momentum has sustained and whether management&#8217;s strategic initiatives are delivering measurable financial outcomes.<\/p><p>At a 1-year return of -20%, the Q4 FY26 results and FY27 guidance commentary will be critical in determining whether the stock can recover toward its 52-week high of Rs 268. Investors will focus on order book updates, margin trajectory, and management tone \u2014 positive surprises on multiple parameters could drive a meaningful re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Q4_FY26_Earnings_Estimates\"><\/span><strong>Piramal Pharma Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-1024x536.jpg\" alt=\"Piramal Pharma Q4 FY26 Analyst Estimates at a Glance  Source MOFSL, YES Securities, JM Financial\" class=\"wp-image-73988\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Analysts covering Piramal Pharma have published Q4 FY26 estimates reflecting sector trends and company-specific catalysts. Consensus points to revenue of Rs 2,400\u20132,600 Cr, PAT of Rs 28\u201355 Cr, and margins of EBITDA 16\u201319%. These projections incorporate Q4 seasonal strength and ongoing business improvements.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 2,204 Cr<\/td><td>Rs 2,400\u20132,600 Cr<\/td><\/tr><tr><td>PAT<\/td><td>Rs -18 Cr<\/td><td>Rs 28\u201355 Cr<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 15.2%<\/td><td>EBITDA 16\u201319%<\/td><\/tr><tr><td>Growth Driver<\/td><td>Base quarter<\/td><td>Recovery catalyst<\/td><\/tr><tr><td>Dividend<\/td><td>Nil<\/td><td>Nil expected<\/td><\/tr><\/tbody><\/table><\/figure><p>Beyond headline numbers, investors should monitor FY27 guidance commentary, working capital trends, and order book visibility. A clean recurring profit print \u2014 rather than one inflated by non-operational items \u2014 carries greater weight with long-term investors.<\/p><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Piramal Pharma<\/a> fundamentals on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Piramal_Pharma_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Piramal Pharma Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CDMO_Revenue_Acceleration\"><\/span><strong>CDMO Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal Pharma&#8217;s CDMO business \u2014 serving global innovator pharma companies with contract manufacturing of complex molecules \u2014 is the highest-growth and highest-margin segment. Q4 FY26 CDMO revenue growth of 15\u201320% YoY would demonstrate that global pharma outsourcing trends are driving demand for Piramal&#8217;s specialised capabilities in complex chemistry.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Complex_Hospital_Generics_CHG_Improvement\"><\/span><strong>Complex Hospital Generics (CHG) Improvement<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The CHG segment \u2014 hospital sterile injectables and anaesthesia products sold in the US and Europe \u2014 has been recovering after prior-year execution challenges. Q4 FY26 CHG revenue growth and gross margin improvement would signal that operational issues have been resolved and the segment is back on a growth trajectory.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"India_Consumer_Healthcare_Revenue\"><\/span><strong>India Consumer Healthcare Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal&#8217;s India consumer healthcare business \u2014 selling OTC brands like Lacto Calamine, Little&#8217;s, and Littles Care \u2014 provides steady domestic revenue. Q4 FY26 will reflect summer-season demand for skin care and baby care products. Growth in this segment supports the overall revenue diversification story.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PAT_Recovery_to_Positive\"><\/span><strong>PAT Recovery to Positive<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal Pharma reported a Q3 FY26 net loss of Rs 18 Cr. Q4 FY26 is expected to see a return to PAT positive \u2014 driven by CDMO revenue growth, CHG operational improvement, and absence of exceptional items. A positive PAT print of Rs 30\u201355 Cr would be the single most important result for investor sentiment.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Debt_Reduction_and_Financial_Health\"><\/span><strong>Debt Reduction and Financial Health<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal Pharma carries significant debt from its CDMO capacity expansion. Q4 FY26 will reflect free cash flow generation and progress on debt reduction. Any improvement in net debt levels \u2014 driven by CDMO contract milestones and CHG recoveries \u2014 would reduce financial risk and improve credit ratings.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Piramal_Pharma_Q4_FY26\"><\/span><strong>5 Risks to Watch in Piramal Pharma Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CDMO_Execution_and_Capacity_Utilisation\"><\/span><strong>CDMO Execution and Capacity Utilisation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>CDMO revenues depend on successfully commissioning new capacity and achieving regulatory approvals for manufacturing sites. Any delays in US FDA approvals or utilisation ramp-up would disappoint CDMO revenue estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CHG_Price_Pressure_in_Sterile_Injectables\"><\/span><strong>CHG Price Pressure in Sterile Injectables<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The US hospital sterile injectable market is competitive. Price erosion in CHG products could offset volume growth and compress margins despite revenue growth.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Regulatory_Risk_%E2%80%94_US_FDA\"><\/span><strong>Regulatory Risk \u2014 US FDA<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal&#8217;s manufacturing facilities are subject to US FDA inspections. Any import alert or warning letter would halt exports to the US market, significantly impacting CDMO and CHG revenues.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"High_Debt_Levels\"><\/span><strong>High Debt Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal Pharma&#8217;s elevated debt levels generate significant interest expenses. Until EBITDA grows sufficiently to comfortably cover debt service, financial risk remains elevated.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"India_Consumer_Healthcare_Competition\"><\/span><strong>India Consumer Healthcare Competition<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The OTC consumer healthcare market is highly competitive with Dabur, Himalaya, and global FMCG players. Market share pressure in India consumer brands could limit the segment&#8217;s growth contribution.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Share_Price_and_Analyst_Ratings\"><\/span><strong>Piramal Pharma Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125832\/image-1156.jpeg\" alt=\"Piramal Pharma Share Price &amp; Analyst Ratings | Source: NSE\/BSE, Broker Notes\" class=\"wp-image-73985\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125832\/image-1156.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125832\/image-1156-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125832\/image-1156-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125832\/image-1156-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125832\/image-1156-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125832\/image-1156-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p>Piramal Pharma is trading at Rs 182 as of early April 2026, against a 52-week high of Rs 268 and 52-week low of Rs 142. Market cap stands at Rs 12,850 Cr. The 1-year return of -20% reflects sector headwinds alongside company-specific factors. Analyst price targets range from the conservative to the optimistic, reflecting differing views on recovery pace and FY27 earnings potential.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Buy<\/td><td>Rs 230<\/td><td>CDMO turnaround story<\/td><\/tr><tr><td>Kotak Inst.<\/td><td>Buy<\/td><td>Rs 225<\/td><td>Complex hospital generics<\/td><\/tr><tr><td>Emkay<\/td><td>Outperform<\/td><td>Rs 218<\/td><td>Margin recovery<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Piramal Pharma&#8217;s live price and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Piramal Pharma Q4 FY26 results will mark a critical milestone \u2014 the company&#8217;s return to profitability after a challenging FY26. At Rs 182, the stock is 32% below its 52-week high. PAT above Rs 40 Cr combined with CDMO revenue acceleration would be the strongest possible result to trigger a re-rating. US FDA inspection outcomes and CHG margin improvement are the key operational watchpoints. Consult a SEBI-registered advisor before investing.<\/p><p>This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.<\/p><p>For more Q4 FY26 previews visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_Q4_results_2026_date\"><\/span><strong>What is the Piramal Pharma Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal Pharma Q4 FY26 results are scheduled for May 2026 (Expected). The board will meet to approve audited financial statements for the quarter ended March 31, 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Piramal Pharma Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Piramal Pharma Q4 FY26 PAT in the range of Rs 28\u201355 Cr, on revenue of Rs 2,400\u20132,600 Cr and margin of EBITDA 16\u201319%. Actual results may differ from these estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Piramal_Pharmas_share_price_ahead_of_Q4_results\"><\/span><strong>What is Piramal Pharma&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal Pharma shares are trading at approximately Rs 182 as of early April 2026. The 52-week high is Rs 268 and 52-week low is Rs 142. The one-year return is -20% and market cap stands at Rs 12,850 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Piramal_Pharma_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Piramal Pharma declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal Pharma is expected to consider Nil expected at the Q4 FY26 board meeting on May 2026 (Expected). The dividend decision reflects management&#8217;s confidence in FY26 free cash flow generation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Piramal_Pharma\"><\/span><strong>Which analysts have a Buy rating on Piramal Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>MOFSL (target Rs 230), Kotak Inst. (target Rs 225), Emkay (target Rs 218) ahead of Q4 FY26 results.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Piramal_Pharma_Q3_FY26_results\"><\/span><strong>What were Piramal Pharma Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, Piramal Pharma reported revenue of Rs 2,204 Cr and PAT of Rs -18 Cr with margins at EBITDA 15.2%. These provided the base for Q4 FY26 analyst estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS announced Q4 FY26 results on April 9, 2026 \u2014 full preview at <a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS Q4 Results 2026<\/a>. <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a> announced results on April 23, 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Piramal_Pharma_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Piramal Pharma a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Piramal Pharma at Rs 182 offers a risk-reward contingent on Q4 execution and FY27 guidance. Investors should review analyst estimates, monitor the results announcement, and consult a SEBI-registered advisor before making investment decisions.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/natural-capsules-q4-results-2026\">Natural Capsules Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/national-fertilizers-q4-results-2026\">National Fertilizers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/national-aluminium-company-q4-results-2026\">National Aluminium Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/nath-bio-genes-india-q4-results-2026\">Nath Bio-Genes (India) Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/narmada-agrobase-q4-results-2026\">Narmada Agrobase Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma (NSE: PPLPHARMA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Piramal Pharma trading at Rs 182 \u2014 against a 52-week high of Rs 268 and a 1-year return of -20% \u2014 the Q4 FY26 results will be a pivotal event for investors tracking the<\/p>\n","protected":false},"author":28,"featured_media":73990,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-73983","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1776670480:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:63:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1156.jpeg\";a:2:{s:2:\"id\";i:73985;s:11:\"source_type\";s:13:\"media-library\";}s:95:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125832\/image-1156.jpeg\";a:2:{s:2:\"id\";i:73985;s:11:\"source_type\";s:13:\"media-library\";}s:145:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial.jpg\";a:2:{s:2:\"id\";i:73988;s:11:\"source_type\";s:13:\"media-library\";}s:154:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-1024x536.jpg\";a:2:{s:2:\"id\";i:73988;s:11:\"source_type\";s:13:\"media-library\";}s:177:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial.jpg\";a:2:{s:2:\"id\";i:73988;s:11:\"source_type\";s:13:\"media-library\";}s:186:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20125955\/Piramal-Pharma-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-1024x536.jpg\";a:2:{s:2:\"id\";i:73988;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["81"],"rank_math_description":["Piramal Pharma Q4 results expected May 2026. Revenue estimate Rs 2,400\u20132,600 Cr, PAT Rs 28\u201355 Cr. CDMO, complex hospital generics and India consumer healthcare preview."],"rank_math_title":["Piramal Pharma Q4 Results 2026: Date, Revenue and CDMO Estimates"],"rank_math_focus_keyword":["Piramal Pharma Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["73990"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8507"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20130230\/Piramal-Pharma-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=73983"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73983\/revisions"}],"predecessor-version":[{"id":73994,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73983\/revisions\/73994"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/73990"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=73983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=73983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=73983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}